Drugs / VARIVAX™ 2007 Process
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01626794 Comparator | Jul 2014 → Oct 2015 | chickenpox | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VARIVAX 2007 Process | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01626794 ↗ |
| Known as | VARIVAX | “This study will test the immunogenicity, safety, and tolerability of VARIVAX™ manufactured with the Varicella Enhanced Process (VEP) compared with the VARIVAX™ 2007 Process.” NCT01626794 ↗ |
| Route | Subcutaneous | “Two 0.5 mL subcutaneous doses administered on Days 1 and 91” NCT01626794 ↗ |